Canada-based rapid health screening solutions provider Predictmedix AI is set to advance diabetes screening with its new AI-driven mobile platform, initially launching in India.
The advanced AI solution offers rapid, non-invasive diabetic risk assessments via smartphone, eliminating the need for traditional blood tests or lab visits.
The platform leverages Predictmedix AI’s in-house technology to provide instant access to millions, focusing on underserved populations.
It combines advanced facial and biometric analysis with smartphone delivery, making diabetic screening accessible, affordable, and scalable.
The development supports Predictmedix AI’s goal of transforming healthcare delivery and promoting the adoption of AI-enabled preventive health solutions.
Key features of the platform include instant diabetic risk scoring, AI-driven facial and biometric analysis, and a user-friendly design with multilingual support.
Additionally, the platform’s secure data handling is compliant with India’s Digital Personal Data Protection (DPDP) Act.
The features aim to capture market share in a high-growth region and generate recurring revenue through direct-to-consumer and B2B channels.
Predictmedix AI’s platform aligns with public health norms of governments, NGOs, and large employers, and enables global scalability with minimal costs through cloud-based delivery.
Predictmedix AI COO Rahul Kushwah said: “We are addressing a critical gap in healthcare access with a cutting-edge solution that empowers individuals to take control of their health using the device they already own — their mobile phone.
“India has over 100 million diabetics and a significant number remain undiagnosed. Our app is designed to bridge that diagnostic divide.”
